[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_112":113},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","ozicpmff6k71jm2cipqa2ozoh","revision",2,"title","SAB Biotherapeutics 的 SAB-142 获 FDA 快速通道资格","originalTitle","SAB Biotherapeutics, Inc. (0001833214) (Filer)","summary","SAB Biotherapeutics, Inc. 于2026年10月13日宣布，美国食品药品监督管理局（FDA）已授予其SAB-142快速通道资格。SAB-142是一种潜在的疾病修饰免疫疗法，用于治疗新发3期1型糖尿病患者。","reason","FDA授予SAB-142快速通道资格，可能加快其在新发3期1型糖尿病治疗中的开发进程。","source",{"_12":103,"_104":105,"_9":106,"_107":42,"_108":109,"_110":111},"links",{"_100":101,"_89":102},"publishedAt","2026-10-13T12:36:10.000Z","discoveredAt","2026-10-13T13:11:18.534Z","timelineAt","category","ai-products","tags",[94,95,96,97,98,99],"stockSymbols",[93],"score",60,"selected",true,"channel","news","story",{"_73":74,"_16":75},"x","readingMode","full","author","language","body",{"_64":88,"_89":-5,"_90":91,"_92":42},"outline",[77,78,79],"relatedStories",[76],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":69,"_70":71,"_72":71},"hasTranslation","bodyLanguage","zh","factId","fpZmrhMSr2_k",{"_73":74,"_16":75},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","f7d59097-a306-44f3-a838-d7651eca2ea2","SAB-142 获 FDA 快速通道资格",{"_73":74,"_16":75},{"_12":86,"_81":87,"_83":15},{"_12":84,"_81":85,"_83":15},{"_12":80,"_81":82,"_83":15},"sec-3","text","第9.01项财务报表和附件","level","sec-2","项目8.01 其他事件。","sec-1","表格 8-K","

美国
证券交易委员会
华盛顿特区 20549

表格 8-K

当前报告

根据1934年证券交易法第13条或第15(d)条

\n \n \n \n \n \n

报告日期（最早事件报告日期）： 2026年10月13日

SAB 生物医药公司

(注册人根据其章程指定的全名)

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n	\n
特拉华州	001-39871	85-3899721
(州或其他司法管辖区的成立地)	(委员会文件编号)	(美国国税局雇主识别号码)

777 W 41st St 401号套房
迈阿密海滩, 佛罗里达州		33140
(主要执行办公室地址)		(邮政编码)

\n \n \n \n \n \n

注册人的电话号码，包括区号： 305 845-2813

\n \n \n \n \n \n

(如果自上次报告以来名称或地址有所更改，请在此处填写原名称或原地址)

如果本次8-K文件旨在同时满足注册人根据以下任何规定下的提交义务，请在下方相应方框中打勾：

☐根据证券法第425条的书面沟通（17 CFR 230.425）

☐根据交易法第14a-12条的征求材料（17 CFR 240.14a-12）

☐根据交易法第14d-2(b)条的开始前沟通（17 CFR 240.14d-2(b)）

☐根据交易法第13e-4(c)条的开始前沟通（17 CFR 240.13e-4(c)）

根据法案第12(b)条注册的证券：

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n	\n
每类的名称		交易符号		每类证券注册的交易所名称
面值为0.0001美元的普通股		SABS		纳斯达克股票市场有限责任公司
每份认股权证可行使一次普通股		SABSW		纳斯达克股票市场有限责任公司

通过勾选方框表明注册人是否为根据1933年证券法第405条（§ 230.405）或1934年证券交易法第12b-2条（§ 240.12b-2）定义的新兴成长公司。

新兴成长公司 ☒

如果为新兴成长公司，请通过勾选方框表明注册人是否已选择不使用根据交易法第13(a)条提供的任何新修订的财务会计标准的延长过渡期。☐

项目8.01 其他事件。

2026年10月13日，特拉华州公司SAB Biotherapeutics, Inc.发布了一则新闻稿（“发布内容”），宣布美国食品药品监督管理局已授予SAB-142快速通道认定。SAB-142是一种潜在的疾病修饰免疫疗法，正在开发用于治疗新诊断的3期1型糖尿病（T1D）患者。本份发布内容作为本8-K表格当前报告的附件99.1提交，并在此引用。

第9.01项财务报表和附件

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n
附件编号	描述
99.1	2026年10月13日SAB Biotherapeutics, Inc.发布的新闻稿。
104	封面页交互式数据文件——封面页XBRL标签已嵌入内联XBRL文档中。

签名

根据1934年证券交易法的要求，注册人已 duly 要求本报告由下文签署人 duly 授权代表签署。

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n
			SAB Biotherapeutics, Inc.

日期：	2026年10月13日	由：	/s/ Samuel J. Reich
			Samuel J. Reich 首席执行官

","original","zhKind","translation","complete","SABS","公司与财报","行业与主题","政策与监管","观点与解读","其他","宏观与美联储","aihot","/items/ozicpmff6k71jm2cipqa2ozoh","https://www.sec.gov/Archives/edgar/data/1833214/000119312526419769/0001193125-26-419769-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792108800&sig=e4adf00b596060d2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792108800&sig=208b33ec2756b0ea 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792108800&sig=786fcd6a5ff8379c 96w","changelogVersion","2026-10-01T08:00"]

表格 8-K

项目8.01 其他事件。

第9.01项 财务报表和附件

第9.01项财务报表和附件